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Proposal for curing multiple sclerosis by genetically engineering oligodendrocytes
Amanda Moses
Department of Biological and Environmental Sciences
Longwood University, Farmville, Virginia
What is Multiple Sclerosis?
• A chronic T cell mediated autoimmune
disease1
• Affects the central nervous system (CNS) by
causing irreversible damage to the myelin
sheath2,3 (Figure 1)
• Two stages4:
1. Relapsing-Remitting
2. Progressive
Possible Causes of Multiple Sclerosis
• CD4+ T cells are activated in the periphery5
(Figure 2)
• B Cells are the key effectors for onset of
the disease5
• Low serum levels of Vitamin D6
• Smoking6
• Childhood obesity6
• Repeated infections of the Epstein-Barr virus6
• Genetics6
Why try to find a cure?
• Current treatments/therapies only slow the
progression of the disease
• ~ 2.5 million people worldwide are affected
- Between 400,000 and 570,000 in the U.S1
• Diagnoses usually occurs between the ages of 20
and 407
• Affects women more commonly than men7 (Figure
3)
• No two cases are the same
Specific Aim
• Find a cure for Multiple Sclerosis through genetically engineering neural stem cells, specifically the 
oligodendrocytes.
• Oligodendrocytes will be treated with chemotherapy in order to forget their memory of Multiple 
Sclerosis
• The three key myelin genes (PLP1, MBP, and MOG) will be introduced to cause remyelination when 
introduced
• Hypothesis: Genetically engineering the neural stem cells will remyelinate the myelin sheath and 
stop lesions from forming.
Methods
Mouse model used 
in study
MRI to determine 
disease activity
Chemotherapy to forget 
memory of M.S
3 key myelin 
genes split into 
txt groups
Response to 
txt measured
Txt response 
tested by MRI and 
amount of lesions
GraphPad Prism 4 and one 
way ANOVA for statistical 
analysis
Potential Pitfalls
• Using neural stem cells for remyelination is a novel concept
• Mice do not respond to any of the three key myelin producing
genes (Figure 4)
• If mice do not respond to the three key myelin producing
genes, change it to the seven myelin peptides
Figure 4. MRI of M.S A 
healthy brain vs a brain that 
has been damaged due to the 
lesions that form as a result 
of multiple sclerosis
Potential Conclusions
• 1.The 3 key meylin producing genes together work as
hypothesized
• 2. Two of the 3 key genes together fix the myelin sheath
• 3. One of the 3 key myelin genes by itself causes remyelination
• For this to support the hypothesis:
- Remyelination occurs
- Disease progression is halted
- No new symptoms occur
- Old symptoms disappear
• If this occurs, then a possible new treatment and cure could
become available (Figure 5).
Figure 3. M.S stats The statistics of who 
Multiple Sclerosis affects and who is at 
the highest risk.
Figure 2. Causes for M.S. The 
possible causes broken down by 
category.
Figure 1. Multiple Sclerosis. The driver for M.S is 
the lesions that form in the myelin sheath causing 
issues in communication between the brain and 
the muscles
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